INT61687

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.00
First Reported 1995
Last Reported 1995
Negated 0
Speculated 0
Reported most in Abstract
Documents 1
Total Number 2
Disease Relevance 0.11
Pain Relevance 1.09

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

transport (Slc3a1) plasma membrane (Slc3a1) carbohydrate metabolic process (Slc3a1)
Anatomy Link Frequency
hippocampal formation 1
medial 1
Pah (Rattus norvegicus)
Slc3a1 (Rattus norvegicus)
Pain Link Frequency Relevance Heat
Enkephalin 10 100.00 Very High Very High Very High
agonist 2 99.98 Very High Very High Very High
opioid receptor 6 99.82 Very High Very High Very High
amygdala 2 92.92 High High
MU agonist 4 91.36 High High
Raphe 2 83.00 Quite High
Thalamus 2 80.16 Quite High
midbrain 2 48.96 Quite Low
Substantia nigra 2 31.36 Quite Low
Antinociceptive 2 25.00 Low Low
Disease Link Frequency Relevance Heat
Nociception 2 54.08 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
At 0.5 microgram and 1 microgram intracerebroventricularly the highly selective mu-opioid receptor agonist D-Ala2, MePhe4, Gly-ol5-enkephalin effected statistically significant increases as well as statistically significant decreases in regional glucose utilization: in limbic structures, such as hippocampal formation, medial amygdala and lateral septum, glucose utilization was most prominently increased after D-Ala2, MePhe4, Gly-ol5-enkephalin; glucose utilization was further increased in the lateral habenular nucleus, the hypothalamus, ventromedial nucleus and dorsal raphe; whereas decreases were found in the mamillary body and anterior thalamus.
MePhe4 Binding (effected) of D-Ala2 in hippocampal formation associated with agonist, thalamus, enkephalin, opioid receptor, raphe and amygdala
1) Confidence 0.00 Published 1995 Journal Brain Res. Section Abstract Doc Link 8593578 Disease Relevance 0.05 Pain Relevance 0.55
At 0.5 microgram and 1 microgram intracerebroventricularly the highly selective mu-opioid receptor agonist D-Ala2, MePhe4, Gly-ol5-enkephalin effected statistically significant increases as well as statistically significant decreases in regional glucose utilization: in limbic structures, such as hippocampal formation, medial amygdala and lateral septum, glucose utilization was most prominently increased after D-Ala2, MePhe4, Gly-ol5-enkephalin; glucose utilization was further increased in the lateral habenular nucleus, the hypothalamus, ventromedial nucleus and dorsal raphe; whereas decreases were found in the mamillary body and anterior thalamus.
MePhe4 Binding (effected) of D-Ala2 in medial associated with agonist, thalamus, enkephalin, opioid receptor, raphe and amygdala
2) Confidence 0.00 Published 1995 Journal Brain Res. Section Abstract Doc Link 8593578 Disease Relevance 0.05 Pain Relevance 0.55

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox